Skip to main content
Top
Published in: European Radiology 7/2022

08-04-2022 | Breast Cancer | Breast

Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy

Authors: Xiaoxia Wang, Yuchuan Tan, Daihong Liu, Hesong Shen, Yongchun Deng, Yong Tan, Lei Wang, Yipeng Zhang, Xin Ma, Xiaohua Zeng, Jiuquan Zhang

Published in: European Radiology | Issue 7/2022

Login to get access

Abstract

Objectives

To investigate the prevalence of chemotherapy-associated steatohepatitis, quantitate the epicardial adipose tissue (EAT) volume in breast cancer patients, and explore the mediating effect of liver fat content on EAT volume in breast cancer patients who received neoadjuvant chemotherapy (NAC).

Methods

From October 2018 to April 2020, patients were retrospectively reviewed and divided into breast cancer non-NAC and NAC groups. The prevalence of chemotherapy-associated steatohepatitis was evaluated through quantitative MRI mDIXON-Quant examinations by using defined proton density fat fraction cutoffs of liver fat. The EAT volume was quantified on chest CT by semi-automatic volume analysis software. Bootstrap analysis was used in the breast cancer NAC group to test the significance of the mediating effect of liver fat content on EAT volume.

Results

A total of 662 breast cancer patients (non-NAC group: 445 patients; NAC group: 217 patients) were included. The prevalence of chemotherapy-associated steatohepatitis in the NAC group was significantly higher than the prevalence of hepatic steatosis in the non-NAC group (42.8% vs. 33.3%, p < 0.001). EAT volume was measured in 561 of 662 breast cancer patients, and was significantly higher in the NAC group than in the non-NAC group (137.26 ± 53.48 mL vs. 125.14 ± 58.77 mL, p = 0.020). In the breast cancer NAC group, the indirect effect of liver fat content on EAT volume was 2.545 (p < 0.001), and the contribution rate to the effect was 69.1%.

Conclusions

EAT volume was significantly higher in the BC-NAC group than in the BC-non-NAC group.

Key Points

The prevalence of CASH was as high as 42.8% in BC patients.
NAC significantly increased the EAT volume in BC patients.
The liver fat content caused the change of EAT volume through mediating effect.
Literature
2.
go back to reference Derks MGM, van de Velde CJH (2018) Neoadjuvant chemotherapy in breast cancer: more than just downsizing. Lancet Oncol 19:2–3PubMedCrossRef Derks MGM, van de Velde CJH (2018) Neoadjuvant chemotherapy in breast cancer: more than just downsizing. Lancet Oncol 19:2–3PubMedCrossRef
3.
go back to reference Gradishar WJ, Anderson BO, Balassanian R et al (2018) Breast cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16:310–320CrossRef Gradishar WJ, Anderson BO, Balassanian R et al (2018) Breast cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 16:310–320CrossRef
4.
go back to reference Banke A, Fosbol EL, Ewertz M et al (2019) Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 7:217–224PubMedCrossRef Banke A, Fosbol EL, Ewertz M et al (2019) Long-term risk of heart failure in breast cancer patients after adjuvant chemotherapy with or without trastuzumab. JACC Heart Fail 7:217–224PubMedCrossRef
5.
go back to reference Matos E, Jug B, Blagus R, Zakotnik B (2016) A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients. Arq Bras Cardiol 107:40–47PubMedPubMedCentral Matos E, Jug B, Blagus R, Zakotnik B (2016) A prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients. Arq Bras Cardiol 107:40–47PubMedPubMedCentral
7.
go back to reference Dash A, Figler RA, Sanyal AJ, Wamhoff BR (2017) Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol 13:193–204PubMedCrossRef Dash A, Figler RA, Sanyal AJ, Wamhoff BR (2017) Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol 13:193–204PubMedCrossRef
8.
9.
go back to reference Vigano L, De Rosa G, Toso C et al (2017) Reversibility of chemotherapy-related liver injury. J Hepatol 67:84–91PubMedCrossRef Vigano L, De Rosa G, Toso C et al (2017) Reversibility of chemotherapy-related liver injury. J Hepatol 67:84–91PubMedCrossRef
10.
go back to reference Inci F, Karatas F (2019) Paclitaxel-induced hepatic steatosis in patients with breast cancer. J BUON 24:2355–2360PubMed Inci F, Karatas F (2019) Paclitaxel-induced hepatic steatosis in patients with breast cancer. J BUON 24:2355–2360PubMed
11.
go back to reference Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(1264-1281):e1264CrossRef Castera L, Friedrich-Rust M, Loomba R (2019) Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156(1264-1281):e1264CrossRef
12.
go back to reference Hui SCN, So HK, Chan DFY et al (2018) Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease. Eur J Radiol 107:7–13PubMedCrossRef Hui SCN, So HK, Chan DFY et al (2018) Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease. Eur J Radiol 107:7–13PubMedCrossRef
13.
go back to reference Yokoo T, Shiehmorteza M, Hamilton G et al (2011) Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 258:749–759PubMedPubMedCentralCrossRef Yokoo T, Shiehmorteza M, Hamilton G et al (2011) Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T. Radiology 258:749–759PubMedPubMedCentralCrossRef
14.
go back to reference Meisamy S, Hines CD, Hamilton G et al (2011) Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 258:767–775PubMedPubMedCentralCrossRef Meisamy S, Hines CD, Hamilton G et al (2011) Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 258:767–775PubMedPubMedCentralCrossRef
15.
go back to reference Chaosuwannakit N, D’Agostino R Jr, Hamilton CA et al (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28:166–172PubMedCrossRef Chaosuwannakit N, D’Agostino R Jr, Hamilton CA et al (2010) Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol 28:166–172PubMedCrossRef
16.
go back to reference Koelwyn GJ, Lewis NC, Ellard SL et al (2016) Ventricular-arterial coupling in breast cancer patients after treatment with anthracycline-containing adjuvant chemotherapy. Oncologist 21:141–149PubMedPubMedCentralCrossRef Koelwyn GJ, Lewis NC, Ellard SL et al (2016) Ventricular-arterial coupling in breast cancer patients after treatment with anthracycline-containing adjuvant chemotherapy. Oncologist 21:141–149PubMedPubMedCentralCrossRef
17.
go back to reference Zhang W, Xie K, Fu S et al (2019) Comparison of the incidence of perioperative cardiovascular risk events among patients with and without a history of neoadjuvant chemotherapy. Minerva Anestesiol 85:822–829PubMed Zhang W, Xie K, Fu S et al (2019) Comparison of the incidence of perioperative cardiovascular risk events among patients with and without a history of neoadjuvant chemotherapy. Minerva Anestesiol 85:822–829PubMed
18.
go back to reference Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552–2565PubMedPubMedCentralCrossRef Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH (2017) Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol 70:2552–2565PubMedPubMedCentralCrossRef
19.
go back to reference Zeng X, Wang X, Chen H et al (2020) Evaluating the image quality of monoenergetic images from dual-energy computed tomography with low-concentration and low-flow-rate contrast media for the arterials supply to the nipple-areola complex in breast cancer compared with conventional computed tomography angiography. J Comput Assist Tomogr 44:921–927PubMedPubMedCentralCrossRef Zeng X, Wang X, Chen H et al (2020) Evaluating the image quality of monoenergetic images from dual-energy computed tomography with low-concentration and low-flow-rate contrast media for the arterials supply to the nipple-areola complex in breast cancer compared with conventional computed tomography angiography. J Comput Assist Tomogr 44:921–927PubMedPubMedCentralCrossRef
20.
go back to reference Eisenberg E, McElhinney PA, Commandeur F et al (2020) Deep learning-based quantification of epicardial adipose tissue volume and attenuation predicts major adverse cardiovascular events in asymptomatic subjects. Circ Cardiovasc Imaging 13:e009829PubMedPubMedCentralCrossRef Eisenberg E, McElhinney PA, Commandeur F et al (2020) Deep learning-based quantification of epicardial adipose tissue volume and attenuation predicts major adverse cardiovascular events in asymptomatic subjects. Circ Cardiovasc Imaging 13:e009829PubMedPubMedCentralCrossRef
21.
go back to reference Russo R, Di Iorio B, Di Lullo L, Russo D (2018) Epicardial adipose tissue: new parameter for cardiovascular risk assessment in high risk populations. J Nephrol 31:847–853PubMedCrossRef Russo R, Di Iorio B, Di Lullo L, Russo D (2018) Epicardial adipose tissue: new parameter for cardiovascular risk assessment in high risk populations. J Nephrol 31:847–853PubMedCrossRef
22.
go back to reference Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE (2020) Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 51:728–736PubMedPubMedCentralCrossRef Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE (2020) Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 51:728–736PubMedPubMedCentralCrossRef
23.
go back to reference Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H (2020) Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res 126:679–704PubMedCrossRef Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H (2020) Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases. Circ Res 126:679–704PubMedCrossRef
24.
go back to reference Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:1724–1745PubMedPubMedCentralCrossRef Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G (2014) Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20:1724–1745PubMedPubMedCentralCrossRef
25.
go back to reference Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20PubMedCrossRef Younossi Z, Anstee QM, Marietti M et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20PubMedCrossRef
26.
go back to reference Tana C, Ballestri S, Ricci F et al (2019) Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health 16 Tana C, Ballestri S, Ricci F et al (2019) Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health 16
27.
go back to reference Kuhn JP, Meffert P, Heske C et al (2017) Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging. Radiology 284:706–716PubMedCrossRef Kuhn JP, Meffert P, Heske C et al (2017) Prevalence of fatty liver disease and hepatic iron overload in a northeastern German population by using quantitative MR imaging. Radiology 284:706–716PubMedCrossRef
28.
go back to reference Kuhn JP, Hernando D, Munoz del Rio A et al (2012) Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology 265:133–142PubMedPubMedCentralCrossRef Kuhn JP, Hernando D, Munoz del Rio A et al (2012) Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology 265:133–142PubMedPubMedCentralCrossRef
29.
go back to reference Kwon EY, Kim YR, Kang DM, Yoon KH, Lee YH (2021) Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography. Clin Imaging 76:53–59PubMedCrossRef Kwon EY, Kim YR, Kang DM, Yoon KH, Lee YH (2021) Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography. Clin Imaging 76:53–59PubMedCrossRef
30.
go back to reference Gaubeta S, Klinghammer L, Jahn D, Schuhback A, Achenbach S, Marwan M (2014) Epicardial fat and coronary artery calcification in patients on long-term hemodialysis. J Comput Assist Tomogr 38:768–772PubMedCrossRef Gaubeta S, Klinghammer L, Jahn D, Schuhback A, Achenbach S, Marwan M (2014) Epicardial fat and coronary artery calcification in patients on long-term hemodialysis. J Comput Assist Tomogr 38:768–772PubMedCrossRef
31.
go back to reference Hell MM, Achenbach S, Schuhbaeck A, Klinghammer L, May MS, Marwan M (2016) CT-based analysis of pericoronary adipose tissue density: relation to cardiovascular risk factors and epicardial adipose tissue volume. J Cardiovasc Comput Tomogr 10:52–60PubMedCrossRef Hell MM, Achenbach S, Schuhbaeck A, Klinghammer L, May MS, Marwan M (2016) CT-based analysis of pericoronary adipose tissue density: relation to cardiovascular risk factors and epicardial adipose tissue volume. J Cardiovasc Comput Tomogr 10:52–60PubMedCrossRef
32.
go back to reference Marwan M, Koenig S, Schreiber K et al (2019) Quantification of epicardial adipose tissue by cardiac CT: influence of acquisition parameters and contrast enhancement. Eur J Radiol 121:108732PubMedCrossRef Marwan M, Koenig S, Schreiber K et al (2019) Quantification of epicardial adipose tissue by cardiac CT: influence of acquisition parameters and contrast enhancement. Eur J Radiol 121:108732PubMedCrossRef
33.
go back to reference Elsanhoury A, Nelki V, Kelle S, Van Linthout S, Tschope C (2021) Epicardial fat expansion in diabetic and obese patients with heart failure and preserved ejection fraction-a specific HFpEF phenotype. Front Cardiovasc Med 8:720690PubMedPubMedCentralCrossRef Elsanhoury A, Nelki V, Kelle S, Van Linthout S, Tschope C (2021) Epicardial fat expansion in diabetic and obese patients with heart failure and preserved ejection fraction-a specific HFpEF phenotype. Front Cardiovasc Med 8:720690PubMedPubMedCentralCrossRef
34.
go back to reference Artz NS, Haufe WM, Hooker CA et al (2015) Reproducibility of MR-based liver fat quantification across field strength: same-day comparison between 1.5T and 3T in obese subjects. J Magn Reson Imaging 42:811–817PubMedPubMedCentralCrossRef Artz NS, Haufe WM, Hooker CA et al (2015) Reproducibility of MR-based liver fat quantification across field strength: same-day comparison between 1.5T and 3T in obese subjects. J Magn Reson Imaging 42:811–817PubMedPubMedCentralCrossRef
35.
go back to reference Serai SD, Dillman JR, Trout AT (2017) Proton density fat fraction measurements at 1.5- and 3-T hepatic MR imaging: same-day agreement among readers and across two imager manufacturers. Radiology 284:244–254PubMedCrossRef Serai SD, Dillman JR, Trout AT (2017) Proton density fat fraction measurements at 1.5- and 3-T hepatic MR imaging: same-day agreement among readers and across two imager manufacturers. Radiology 284:244–254PubMedCrossRef
36.
go back to reference Tang A, Tan J, Sun M et al (2013) Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267:422–431PubMedPubMedCentralCrossRef Tang A, Tan J, Sun M et al (2013) Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267:422–431PubMedPubMedCentralCrossRef
37.
go back to reference Jayakumar S, Middleton MS, Lawitz EJ et al (2019) Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol 70:133–141PubMedCrossRef Jayakumar S, Middleton MS, Lawitz EJ et al (2019) Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol 70:133–141PubMedCrossRef
38.
go back to reference Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353PubMedCrossRef Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353PubMedCrossRef
39.
go back to reference Lancellotti P, Anker SD, Donal E et al (2015) EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging 16:466–470PubMedCrossRef Lancellotti P, Anker SD, Donal E et al (2015) EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology. Eur Heart J Cardiovasc Imaging 16:466–470PubMedCrossRef
40.
go back to reference Madonna R, Massaro M, Scoditti E, Pescetelli I, De Caterina R (2019) The epicardial adipose tissue and the coronary arteries: dangerous liaisons. Cardiovasc Res 115:1013–1025PubMedCrossRef Madonna R, Massaro M, Scoditti E, Pescetelli I, De Caterina R (2019) The epicardial adipose tissue and the coronary arteries: dangerous liaisons. Cardiovasc Res 115:1013–1025PubMedCrossRef
41.
go back to reference Packer M (2018) Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 71:2360–2372PubMedCrossRef Packer M (2018) Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol 71:2360–2372PubMedCrossRef
42.
go back to reference Christensen RH, von Scholten BJ, Hansen CS et al (2019) Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. Cardiovasc Diabetol 18:114PubMedPubMedCentralCrossRef Christensen RH, von Scholten BJ, Hansen CS et al (2019) Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes. Cardiovasc Diabetol 18:114PubMedPubMedCentralCrossRef
43.
go back to reference Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153PubMedCrossRef Adams LA, Anstee QM, Tilg H, Targher G (2017) Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:1138–1153PubMedCrossRef
44.
go back to reference van den Berg EH, Wolters AAB, Dullaart RPF et al (2019) Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int 39:1343–1354PubMedPubMedCentralCrossRef van den Berg EH, Wolters AAB, Dullaart RPF et al (2019) Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. Liver Int 39:1343–1354PubMedPubMedCentralCrossRef
45.
go back to reference Xia LY, Hu QL, Zhang J, Xu WY, Li XS (2020) Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol 18:129PubMedPubMedCentralCrossRef Xia LY, Hu QL, Zhang J, Xu WY, Li XS (2020) Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36,480 cases. World J Surg Oncol 18:129PubMedPubMedCentralCrossRef
46.
go back to reference Idilman IS, Aniktar H, Idilman R et al (2013) Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 267:767–775PubMedCrossRef Idilman IS, Aniktar H, Idilman R et al (2013) Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 267:767–775PubMedCrossRef
Metadata
Title
Chemotherapy-associated steatohepatitis was concomitant with epicardial adipose tissue volume increasing in breast cancer patients who received neoadjuvant chemotherapy
Authors
Xiaoxia Wang
Yuchuan Tan
Daihong Liu
Hesong Shen
Yongchun Deng
Yong Tan
Lei Wang
Yipeng Zhang
Xin Ma
Xiaohua Zeng
Jiuquan Zhang
Publication date
08-04-2022
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 7/2022
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-022-08581-1

Other articles of this Issue 7/2022

European Radiology 7/2022 Go to the issue